ArticleClinical kidney journal2026
Calcimimetic and vitamin D receptor agonist therapy associates with lower mortality and fractures in hemodialysis patients: an international DOPPS analysis.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Evidence linking chronic kidney disease-mineral and bone disorder (CKD-MBD) therapies to hard clinical outcomes in hemodialysis remains limited. Treatment with vitamin D receptor activators (VDRAs) and calcimimetics is often adjusted or discontinued in response to parathyroid hormone values, which complicates the evaluation of their associations with clinical outcomes in observational research. Methods: Because VDRA/calcimimetic prescriptions change over time in response to CKD-MBD markers that also predict outcomes, data from Phases IV-VII (2009-2022) of the Dialysis Outcomes and Practice Patterns Study were analyzed using marginal structural models with time-updated, four-category exposure status (neither use, VDRA only, calcimimetics only, or both) to investigate the hazard ratios (HRs) associated with all-cause mortality, cardiovascular disease (CVD) mortality, bone fractures, and hip fractures. Results: A total of 117 452 hemodialysis patients were included in the all-cause mortality analysis, 50 111 patients in the CVD mortality analysis, and 33 906 patients in the fracture analysis. Compared with neither use, VDRA-only use (HR 0.71, Conclusions: Calcimimetics and combination therapy were associated with lower fracture risk in addition to lower mortality, but these findings should be interpreted cautiously and regarded as hypothesis-generating.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.